Actively Recruiting
Studying Lipoprotein A Levels to Assess Cardiovascular Risk in Stage 4 Chronic Kidney Disease Patients Without Dialysis
Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2026-10-20
300
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the blood level of lipoprotein A Lpa, which is linked to certain gene mutations and associated with increased risk of heart and blood vessel problems like heart attacks, strokes, and aortic valve issues. This study focuses on people with stage 4 chronic kidney disease CKD who are not yet on dialysis, as they are at high risk for cardiovascular problems. The goal is to understand how Lpa levels vary in this group and whether high levels relate to heart and kidney events over 18 months. Participants will have their blood tested to measure Lpa levels in mmoll. The study tracks these patients without any treatment intervention, observing outcomes such as heart attacks, strokes, peripheral artery disease, and the start of kidney replacement therapy. The main interest is whether high Lpa levels at the start predict these events over an 18-month period. Throughout the study, participants will be followed for 18 months to monitor the occurrence of cardiovascular and kidney-related events. Researchers will review medical history and outcomes like heart-related deaths, first heart attacks, strokes, progression of artery disease, and kidney therapy starts. The study also looks at prior cardiovascular conditions and hospitalizations. Participants health will be tracked to better understand how Lpa levels relate to these risks.
CONDITIONS
Brief Title
Hyperlipoproteinemia A as a Marker of Cardiovascular Risk in Patients With Stage 4 Chronic Kidney Disease
Research Team
O
Olivier Moranne
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here